A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Public ClinicalTrials.gov record NCT03066804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Study identification
- NCT ID
- NCT03066804
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,572 participants
Conditions and interventions
Interventions
- sacubitril/valsartan Drug
- Enalapril Drug
- Valsartan Drug
- Placebo to match sacubitril/valsartan Drug
- Placebo to match enalapril Drug
- Placebo to match valsartan Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2017 (Actual)
- Primary completion
- Oct 28, 2019 (Actual)
- Completion
- Oct 28, 2019 (Actual)
- Last update posted
- Oct 11, 2021
2017 – 2019
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Andalusia | Alabama | 36420 | — |
| Novartis Investigative Site | Mobile | Alabama | 36608 | — |
| Novartis Investigative Site | Beverly Hills | California | 90211 | — |
| Novartis Investigative Site | Long Beach | California | 90813 | — |
| Novartis Investigative Site | Santa Ana | California | 92704 | — |
| Novartis Investigative Site | Sylmar | California | 91342 | — |
| Novartis Investigative Site | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | Stamford | Connecticut | 06905 | — |
| Novartis Investigative Site | Bradenton | Florida | 34209 | — |
| Novartis Investigative Site | Gainesville | Florida | 32608 | — |
| Novartis Investigative Site | Hollywood | Florida | 33312 | — |
| Novartis Investigative Site | Miami | Florida | 33133 | — |
| Novartis Investigative Site | Port Orange | Florida | 32127 | — |
| Novartis Investigative Site | Thomasville | Georgia | 31792 | — |
| Novartis Investigative Site | Arlington Heights | Illinois | 60004 | — |
| Novartis Investigative Site | Alexandria | Louisiana | 71301 | — |
| Novartis Investigative Site | Chalmette | Louisiana | 70043 | — |
| Novartis Investigative Site | Houma | Louisiana | 70360 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68526 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68114 | — |
| Novartis Investigative Site | Rochester | New York | 14621 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Corvallis | Oregon | 97330 | — |
| Novartis Investigative Site | Abington | Pennsylvania | 19001 | — |
| Novartis Investigative Site | Sioux Falls | South Dakota | 57104 | — |
| Novartis Investigative Site | Jackson | Tennessee | 38301 | — |
| Novartis Investigative Site | Dallas | Texas | 75234 | — |
| Novartis Investigative Site | Lufkin | Texas | 75904 | — |
| Novartis Investigative Site | Tomball | Texas | 77375 | — |
| Novartis Investigative Site | Falls Church | Virginia | 22042 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 348 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03066804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2021 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03066804 live on ClinicalTrials.gov.